Chabiotech Co.,Ltd. (085660.KQ)
KRW 15280.0
(-2.98%)
KRW 15280.0
(-2.98%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 388.94 Billion KRW | 16.36% |
| 2022 | 334.25 Billion KRW | 58.18% |
| 2021 | 211.31 Billion KRW | 14.16% |
| 2020 | 185.1 Billion KRW | 74.06% |
| 2019 | 106.34 Billion KRW | 156.31% |
| 2018 | 41.48 Billion KRW | 700.54% |
| 2017 | -6.9 Billion KRW | -109.49% |
| 2016 | 72.77 Billion KRW | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | 343.39 Billion KRW | -14.85% |
| 2024 Q1 | 405.75 Billion KRW | 4.32% |
| 2023 Q1 | 350.02 Billion KRW | 4.72% |
| 2023 FY | 388.94 Billion KRW | 16.36% |
| 2023 Q4 | 388.94 Billion KRW | -1.85% |
| 2023 Q3 | 396.27 Billion KRW | 9.66% |
| 2023 Q2 | 361.36 Billion KRW | 3.24% |
| 2022 Q2 | 248.09 Billion KRW | 13.85% |
| 2022 Q4 | 334.25 Billion KRW | -4.27% |
| 2022 Q3 | 349.15 Billion KRW | 40.74% |
| 2022 FY | 334.25 Billion KRW | 58.18% |
| 2022 Q1 | 217.9 Billion KRW | 3.12% |
| 2021 Q3 | 223.21 Billion KRW | 0.0% |
| 2021 Q4 | 211.31 Billion KRW | -5.33% |
| 2021 FY | 211.31 Billion KRW | 14.16% |
| 2020 FY | 185.1 Billion KRW | 74.06% |
| 2019 FY | 106.34 Billion KRW | 156.31% |
| 2018 FY | 41.48 Billion KRW | 700.54% |
| 2017 FY | -6.9 Billion KRW | -109.49% |
| 2016 FY | 72.77 Billion KRW | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| HLB Co., Ltd. | -46.18 Billion KRW | 942.173% |
| iNtRON Biotechnology, Inc. | -40.58 Billion KRW | 1058.349% |
| BINEX Co., Ltd. | 45.34 Billion KRW | -757.697% |
| Bioneer Corporation | -3.9 Billion KRW | 10053.037% |
| Anterogen.Co.,Ltd. | 8.35 Billion KRW | -4557.012% |
| MEDIPOST Co., Ltd. | 14.81 Billion KRW | -2525.459% |
| CrystalGenomics, Inc. | 8.99 Billion USD | -4225.487% |
| Helixmith Co., Ltd | -24.42 Billion KRW | 1692.349% |
| Medy-Tox Inc. | 49.58 Billion KRW | -684.409% |
| Peptron, Inc. | 4.86 Billion KRW | -7888.773% |
| Amicogen, Inc. | 125.26 Billion KRW | -210.502% |
| Genexine, Inc. | 61.39 Billion KRW | -533.504% |
| HLB Therapeutics Co.,Ltd. | -13.68 Billion KRW | 2941.748% |
| LegoChem Biosciences, Inc. | -56.05 Billion KRW | 793.879% |
| ALTEOGEN Inc. | 53.56 Billion KRW | -626.048% |
| PharmaResearch Co., Ltd. | -32.93 Billion KRW | 1280.821% |
| SillaJen, Inc. | -13.89 Billion KRW | 2899.85% |
| JETEMA, Co., Ltd. | 84.27 Billion KRW | -361.494% |
| OliX Pharmaceuticals,Inc | 27.37 Billion KRW | -1320.81% |
| Genomictree Inc. | -43.43 Billion KRW | 995.459% |
| MedPacto, Inc. | -64 Billion KRW | 707.72% |
| D&D Pharmatech | -7.5 Billion KRW | 5280.524% |
| EASY BIO,Inc. | 53.21 Billion KRW | -630.952% |
| GI Innovation, Inc. | -4.82 Billion KRW | 8165.177% |